$CLDX News

HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $42 Price Target

Reported Sunday, Celldex Presents Phase 1 CDX-622 Data At EAACI 2026 Showing Bispecific Antibody Targeting Soluble SCF And TSLP Achieves Profound Mast Cell Depletion With Favorable Safety Profile

Reported Sunday, Celldex Presents Phase 2 Data Showing Up To 64% Of Barzolvolimab-Treated CSU Patients Remained Angioedema-Free Seven Months After Last Dose At EAACI Annual Meeting

Celldex Therapeutics (CLDX) Stock Valuation Check After Recent Share Price Momentum

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting

Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress

Celldex To Highlight Three Presentations From Barzolvolimab And CDX-622 Programs At EAACI Annual Congress 2026

UBS Maintains Buy on Celldex Therapeutics, Raises Price Target to $45

Celldex Therapeutics Inc (NASDAQ:CLDX) Shows Strong Technical Breakout Setup

Wells Fargo Maintains Overweight on Celldex Therapeutics, Raises Price Target to $54

Assessing Celldex Therapeutics (CLDX) Valuation After Recent Share Price Pullback And Mixed Signals

Barclays Maintains Overweight on Celldex Therapeutics, Raises Price Target to $48

Celldex Reports First Quarter Financial Results and Provides Corporate Update

Celldex Therapeutics Q1 EPS $(1.18) Beats $(1.20) Estimate, Sales $15.000K Miss $972.222K Estimate

Celldex: A Mast Cell Reset Story Hiding Inside A CSU Trial

Wall Street Analysts See a 76.42% Upside in Celldex (CLDX): Can the Stock Really Move This High?

Is Celldex Therapeutics (CLDX) Still Attractive After A 70% One Year Share Price Jump

Barclays Upgrades Celldex Therapeutics to Overweight, Raises Price Target to $45

Celldex Therapeutics Spotlights Barzolvolimab as Phase III CSU Data Looms After Fast Enrollment